Anticonvulsant and anxiolytic-like effects of compounds isolated from Polygala sabulosa (Polygalaceae) in rodents: In vitro and in vivo interactions with benzodiazepine binding sites

Psychopharmacology

Volumn 197, Issue 3, 2008, Pages 351-360

  Duarte, Filipe Silveira ^a   Marder, Mariel ^b   Hoeller, Alexandre Ademar ^a   Duzzioni, Marcelo ^a   Mendes, Beatriz Garcia ^a   Pizzolatti, Moacir Geraldo ^a   De Lima, Thereza Christina Monteiro ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Anticonvulsant; Anxiolytic; Benzodiazepine site; Phytomedicines; Polygala sabulosa

Indexed keywords

ACETIC ACID ETHYL ESTER; ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; DIAZEPAM; DIENPAX; FLUMAZENIL; FLUNITRAZEPAM; HYPNOTIC SEDATIVE AGENT; PENTETRAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CONVULSION; CORTICAL BONE; DRUG BINDING SITE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ELECTRIC SHOCK; ELECTROENCEPHALOGRAM; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; POLYGALACEAE; PRIORITY JOURNAL; RAT; RODENT; SYNAPTOSOME;

ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; AROUSAL; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; ELECTROSHOCK; FEAR; INJECTIONS, INTRAVENTRICULAR; MALE; MAZE LEARNING; MICE; PENTYLENETETRAZOLE; PLANT EXTRACTS; POLYGALA; PYRONES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, GABA-A; SEIZURES;

EID: 43149095155     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-1037-z     Document Type: Article

References (35)

1. Ashton H (1994) Guidelines for the rational use of benzodiazepines. When and what to use. Drugs 48(1):25-40
2. Blumenthal M (2002) Kava safety questioned due to case reports of liver toxicity. HerbalGram 55:26-32
3. Brauer RB, Stangl M, Stewart JR, Pfab R, Becker K (2003) Acute liver failure after administration of herbal tranquilizer kava-kava (Piper methysticum). J Clin Psychiatry 64(2):216-218
4. Clenet F, Hascoet M, Fillion G, Galons H, Bourin M (2005) Role of GABA-ergic and serotonergic systems in the anxiolytic-like mechanism of action of a 5-HT-moduline antagonist in the mouse elevated plus maze. Behav Brain Res 158(2):339-348
5. Cole JC, Rodgers RJ (1994) Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behaviour of mice in the elevated plus-maze. Pharmacol Biochem Behav 52(3):473-478
6. Crestani F, Martin JR, Mohler H, Rudolph U (2000) Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol 131(7):1251-1254
7. Dhawan K, Dhawan S, Sharma A (2004) Anti-anxiety studies on extracts of Passiflora incarnata Linneaus. J Ethnopharmacol 78(2-3):165-170
8. Duarte FS, Duzzioni M, Mendes BG, Pizzolatti MG, De Lima TC (2007) Participation of dihydrostyryl-2-pyrones and styryl-2-pyrones in the central effects of Polygala sabulosa (Polygalaceae), a folk medicine topical anesthetic. Pharmacol Biochem Behav 86(1):150-161
9. Escher M, Desmeules J, Giostra E, Mentha G (2001) Hepatitis associated with Kava, a herbal remedy for anxiety. BMJ 322(7279):139
10. Haley TJ, McCormick WG (1957) Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol 12(1):12-15
11. Hui KM, Huen MSY, Wang HY, Zheng H, Sigel E, Baur R, Ren H, Li ZW, Wong JT-F, Xue H (2002) Anxiolytic effect of wongonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi. Biochem Pharmacol 64(9):1415-1424
12. Ishizawa Y, Furuya K, Yamagishi S, Dohi S (1997) Non-GABAergic effects of midazolam, diazepam and flumazenil on voltage-dependent ion currents in NG108-15 cells. Neuroreport 8(11):2635-2638
13. Kupferberg HJ (1992) Strategies for identifying and developing new anticonvulsant drugs. Pharm Weekbl Sci 14(3A):132-138
14. Leung WC, Zheng H, Huen M, Law SK, Xue H (2003) Anxiolytic-like action of orally administered dl-tetrahydropalmatine in elevated plus-maze. Prog Neuro-Psychopharmacol. Biol Psychiatry 27(5):775-779
15. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 92(2):180-185
16. Löscher W (2002) Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16(10):669-694
17. A/benzodiazepine receptor heterogeneity: neurophysiological implications. Neuropharmacology 34(3):245-254
18. MacDonald RL, Kelly KM (1995) Antiepileptic drug mechanisms of action. Epilepsia 36(2):S2-12
19. Mandhane SN, Aavula K, Rajamannar T (2007) Timed pentylenetetrazol infusion test: A comparative analysis with s.c. PTZ and MES models of anticonvulsant screening in mice. Seizure 16(7):636-644
20. Marder M, Viola H, Wasowski C, Fernandez S, Medina JH, Paladini AC (2003) 6-methylapigenin and hesperidin: new valeriana flavonoids with activity on the CNS. Pharmacol Biochem Behav 75(3):537-545
21. Maurice T, Lockhart BP, Privat A (1996) Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706(2):181-193
22. Medina JH, Paladin AC, Wolfman C, Levi de Stein M, Calvo D, Diaz LE, Pena C (1990) Chrysin (5,7-di-OH-flavone), a naturally-occurring ligand for benzodiazepine receptors, with anticonvulsant properties. Biochem Pharmacol 40(10):2227-2231
23. Möhler H (2006) GABAA receptors in central nervous system disease: anxiety, epilepsy, and insomnia. J Recept Signal Transduct Res 26(5-6):731-740
24. Nutt DJ, Malizia AL (2001) New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 179:390-396
25. Polc P (1991) GABA-independent mechanisms of benzodiazepine action. In: File SE, Briley M (eds) New concepts in anxiety. London, MacMillan Publishers, pp 211-236
26. Racine RJ (1972) Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 32(3):281-294
27. Rodgers RJ, Dalvi A (1997) Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev 21(6):801-810
28. Rogawski MA, Porter RJ (1990) Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 42(3):223-286
29. Russmann S, Lauterburg BH, Helbling A (2001) Kava hepatotoxicity. Ann Intern Med 135(1):68-9
30. Singh YN (2005) Potential for interaction of kava and St. John's wort with drugs. J Ethnopharmacol 100(1-2):108-13
31. Starr KR, Price GW, Watson JM, Atkinson PJ, Arban R, Melotto S, Dawson LA, Hagan JJ, Upton N, Duxon MS (2007) SB-649915-B, a Novel 5-HT(1A/B) Autoreceptor Antagonist and Serotonin Reuptake Inhibitor, is Anxiolytic and Displays Fast Onset Activity in the Rat High Light Social Interaction Test. Neuropsychopharmacology 32(10):2163-2172
32. Subramaniam S, Rho JM, Penix L, Donevan SD, Fielding RP, Rogawski MA (1995) Felbamate block of the N-methyl-D-aspartate receptor. J Pharmacol Exp Ther 273(2):878-886
33. Swinyard EA, Brown WC, Goodman LS (1952) Comparative assays of antiepileptic drugs in mice and rats. J Pharmacol Exp Ther 106(3):319-330
34. Viola H, Marder M, Wasowski C, Giorgi O, Paladini AC, Medina JH (2000) 6,3′-dibromoflavone and 6-nitro-3′-bromoflavone: new additions to the 6,3′-disubstituted flavone family of high-affinity ligands of the brain benzodiazepine binding site with agonistic properties. Biochem Biophys Res Commun 273(2):694-698
35. Zhang ZJ (2004) Therapeutic effects of herbal extracts and constituents in animal models of psychiatric disorders. Life Sci 75(14):1659-1699